newsfilter
← Earnings
Earnings Releases·

Acadia Pharmaceuticals — Third Quarter 2026 Earnings Summary

Acadia Pharmaceuticals reported third-quarter 2026 GAAP total revenues of $342 million, representing a 22% increase compared to the same period in 2025. Net sales for DAYBUE reached $140 million, a 39% year-over-year rise driven by strong adoption of DAYBUE STIX, while NUPLAZID sales totaled $202 million, up 12% on a non-GAAP adjusted basis. The company raised its full-year 2026 DAYBUE net sales guidance to a range of $505–$520 million and narrowed its NUPLAZID and total revenue ranges. Additionally, Acadia announced Phase 3-enabling results for remlifanserin in Alzheimer's disease psychosis and received FDA Fast Track designation for the drug's potential use in Lewy body dementia psychosis.

Company
ACADIA PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology